EMA Authorised: Yorvipath (palopegteriparatide) — Ascendis Pharma Bone Diseases A/S

View source ↗

Summary

The EMA has authorised Yorvipath (palopegteriparatide) from Ascendis Pharma Bone Diseases A/S for the treatment of hypoparathyroidism and has granted orphan med…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• YORVIPATH (palopegteriparatide)

Snippet

Status: Authorised. Therapeutic area: Hypoparathyroidism. MAH: Ascendis Pharma Bone Diseases A/S. Decision date: 10/04/2025. Orphan medicine